[1] Alisi A,Cianfarani S,Manco M,et al. Non-alcoholic fatty liver disease and metabolic syndrome in adolescents:pathogenetic role of genetic background and intrauterine environment. Ann Med,2012,44(1):29-40. [2] 浙江省脂肪肝和酒精肝协作组.复方牛胎肝提取物治疗非酒精性脂肪性肝病的多中心临床研究.临床肝胆病杂志,2011,27(2):166-173 . [3] 沈峰,丁晓东,范建高. 美国非酒精性脂肪性肝病诊疗指南简介. 实用肝脏病杂志,2012,15(4):362-363. [4] 王春霞,麦韵屏, 沙卫红,等. 体检人群非酒精性脂肪性肝病检出率及其相关因素分析. 实用肝脏病杂志,2012,15(4):289-290. [5] Souza MR,Diniz MF,Medeiros-Filho JE,et al. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol,2012,49(1):89-96. [6] 谭彦芳, 赵彩彦. 非酒精性脂肪肝病药物治疗进展.实用肝脏病杂志,2013,16(4):378-381. [7] Alisi A,Nobili V. Non-alcoholic fatty liver disease in children now:lifestyle changes andpharmacologic treatments. Nutrition,2012,28(8):722-726. [8] Yilmaz Y. Fructose in non-alcoholic fatty liver disease. Aliment Pharmacol Ther,2012,35(10):1135-1144. [9] 黄卫东, 高卓维, 殷鑫, 等.肝脂平联合复方牛胎肝提取物片治疗非酒精性脂肪肝的临床观察. 湖北中医杂志,2010,32(12):13-14. [10] 李烨,黄腊平,彭红兵,等. 非酒精性脂肪肝的中西医结合治疗.中国临床实用医学,2010,4(1):199-201. [11] Gressner OA,Weiskirchen R,Gressner AM. Biomarkers of liver fibrosis:clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta,2007,381(2):107-113. [12] Juriens I,Rigaux J,Blero D. Nonalcoholic fatty liver disease assessment. Rev Med Brux,2012,33(4):205-211. [13] 蔡卫民, 陶君, 张彬彬, 等.复方牛胎肝提取物片抗肝纤维化的实验研究. 中华肝脏病杂志,2004,12(8):499. [14] Chuthan SA,Pagadala MR,Kirwan JP. Management of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol,2013,59(1):69-87. [15] Martinson BC,Crain AL,Sherwood NE,et al. Population reach and recruitment bias in a maintenance RCT in physically active older adults. J Phys Act Health, 2010,7(1):127-135. |